Novel in Vivo and in Vitro Pharmacokinetic/Pharmacodynamic-Based Human Starting Dose Selection for Glofitamab

Obinutuzumab plus Chlorambucil in Patients with CLL and Coexisting Conditions

Valentin Goede, Kirsten Fischer, Raymonde Busch et al. · New England Journal of Medicine · 2014 · 1.5K citations · Full text

Pharmacy, Hematology, Pharmacotherapy +16

Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell–mediated B-cell cytotoxicity

Ekkehard Mössner, Peter Brünker, Samuel Moser et al. · Blood · 2010 · 957 citations · Full text

Life Sciences, Immunology, Oncology +17

Obinutuzumab for the First-Line Treatment of Follicular Lymphoma

Robert Marcus, Andrew Davies, Kiyoshi Ando et al. · New England Journal of Medicine · 2017 · 788 citations · Full text

Medicine, Immunology, Oncology +14

Obinutuzumab or Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Previously Untreated Diffuse Large B-Cell Lymphoma

Umberto Vitolo, Marek Trněný, David Belada et al. · Journal of Clinical Oncology · 2017 · 424 citations

Medicine, Hematology, Oncology +12

Bispecific T-Cell Engager (BiTE) Antibody Construct Blinatumomab for the Treatment of Patients With Relapsed/Refractory Non-Hodgkin Lymphoma: Final Results From a Phase I Study

Maria-Elisabeth Goebeler, Stefan Knop, Andreas Viardot et al. · Journal of Clinical Oncology · 2016 · 421 citations

Medicine, Hematology, Oncology +17